Skip to main content
Log in

Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The primary metabolite of cyclophosphamide (CP, 1), i.e. 4-hydroxy-CP 2, has high pharmacological activity, but it is a very unstable compound. Chemical approaches to the stabilization involved in the substitution of the hydroxy group at the C 4-position, especially by a sulfoalkylthio-moiety. Within this new class of compounds ASTA Z 7557 (2-(bis-(2-chloroethyl))-amino-cis-4-((2-sulfoethyl)-thio)-tetrahydro-2H-1,3,2-oxazaphosphorine-r-2-oxide cyclohexylamine salt, i.e. cis-4-sulfoethylthio-CP, cis-13) was chosen for further evaluation. Cis-13 was synthesized by condensation of compound 2 and 2-mercapto-ethanesulfonic acid cyclohexylamine salt 14 in aqueous acetone yielding the cis-isomer with high stereoselectivity. It is a white crystalline powder, m.p. 126–134°C, stable at room temperature, with a solubility of 16% in water. The stereochemistry was confirmed by NMR-data and X-ray diffraction. In 0.07 M phosphate buffer at pH 7 and 37°C cis-13 isomerizes to the epimer trans-13, equilibrating at a cis-trans-ratio of 59 to 41 within less than 5 minutes. Simultaneously a rapid initial hydrolysis occurs to 2 and 14 followed by a time period with lower degradation due to the decomposition of 2. The rate of release of 2 increases with decreasing concentration and especially by addition of an oxidant. It could be retarded by addition of the corresponding thiol mesna, sodium 2-mercapto-ethanesulfonate 15, or of another thiol. In the presence of 3-mercapto-propane sulfonate 13 yielded 4-(3-sulfopropyl)thio-CP17.

With changing pH values from 2 to 9, the lowest hydrolytic speed was observed at pH 4.0 to 4.3. For clinical use cis-13 is prepared as a lyophilisate containing additional sodium citrate buffer to guarantee this optimal pH value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brock N: Oxazaphosphorine cytostatics: structure-activity relationships, selectivity and metabolism, regional detoxification. In DN Reinhoudt, TA Connors, HM Pinedo and KW van de Poll (eds): Structure-activity relationships of anti-tumor agents. Martinus Nijhoff Publishers, The Hague, Boston, London, 1983, pp 239–267

    Google Scholar 

  2. Colvin M, Brundrett RB, Kan M-NN, Jardine I, Fenselau C: Alkylating properties of phosphoramide mustard. Cancer Res 36:1121–1126, 1976

    Google Scholar 

  3. Takamizawa A, Matsumoto S, Iwata T, Kentagiri K, Tochino Y, Yamaguchi K: Studies on cyclophosphamide metabolites and their related compounds II. Preparation of an active species of cyclophosphamide and some related compounds. J Amer Chem Soc 95:985–986, 1973

    Google Scholar 

  4. Peter G, Wagner T, Hohorst H-J: Studies on 4-hydro-peroxy-cyclophosphamide (NSG-181815): A simple preparation method and its application for the synthesis of a new class of “activated” sulfur-containing cyclophosphamide (NSC-26271) derivatives. Cancer Treat Rep 60:429–435, 1976

    Google Scholar 

  5. Hirano T, Klesse W, Heusinger GH, Lambert G, Ringsdorf H: Synthesis of activated cyclophosphamide derivatives. Tetrahedron Lett: 883–886, 1979

  6. Scheffler G, Niemeyer U, Brock N, Pohl J: Oxazaphos-phorin-4-thio-alkansulfonsäuren und deren neutrale Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen. Ger Offen 31 11 428, Asta Werke AG, Anm 24.3.1981

  7. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G: Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneim-Forsch/Drug Res 29:659–661, 1979

    Google Scholar 

  8. Low FJ, Borch RF, Sladek NE: Conversion of 4-hydro-peroxy-cyclophosphamide and 4-hydroxy-cyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts. Cancer Res 42:830–837, 1982

    Google Scholar 

  9. Draeger U, Peter G, Hohorst H-J: Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds. Cancer Treat Rep 60:355–359, 1976

    Google Scholar 

  10. Peter G, Hohorst H-J: Synthesis and preliminary antitumor evaluation of 4-(SR)-sulfido-cyclophosphamides. Cancer Chemother Pharmacol 3:181–188, 1979

    Google Scholar 

  11. Hirano T, Ringsdorf H, Zaharko DS: Antitumor activity of monomeric and polymeric cyclophosphamide derivatives compared with in vitro hydrolysis. Cancer Res 40:2263–2267, 1980

    Google Scholar 

  12. Ellman GL: Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–77, 1959

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niemeyer, U., Engel, J., Scheffler, G. et al. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide. Invest New Drugs 2, 133–139 (1984). https://doi.org/10.1007/BF00232342

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00232342

Key words

Navigation